SMO — Smoothened, Frizzled Class Receptor

Overview

flowchart TD
    SMO["SMO"] -->|"associated with"| Ameloblastoma["Ameloblastoma"]
    SMO["SMO"] -->|"therapeutic target"| Hedgehog["Hedgehog"]
    SMO["SMO"] -->|"therapeutic target"| Cancer["Cancer"]
    SMO["SMO"] -->|"therapeutic target"| Als["Als"]
    SMO["SMO"] -->|"therapeutic target"| Sonic_Hedgehog["Sonic Hedgehog"]
    SMO["SMO"] -->|"therapeutic target"| Ms["Ms"]
    SMO["SMO"] -->|"implicated in"| Cancer["Cancer"]
    SMO["SMO"] -->|"implicated in"| Carcinoma["Carcinoma"]
    SMO["SMO"] -->|"implicated in"| Medulloblastoma["Medulloblastoma"]
    SMO["SMO"] -->|"therapeutic target"| Prostate_Cancer["Prostate Cancer"]
    SMO["SMO"] -->|"inhibits"| Carcinoma["Carcinoma"]
    SMO["SMO"] -->|"activates"| Colorectal_Cancer["Colorectal Cancer"]
    SMO["SMO"] -->|"activates"| Cancer["Cancer"]
    SMO["SMO"] -->|"activates"| Tumor["Tumor"]
    style SMO fill:#4fc3f7,stroke:#333,color:#000

SMO (Smoothened, Frizzled Class Receptor) encodes a 793 amino acid class F G protein-coupled receptor (GPCR) that serves as the essential signal transducer of the Hedgehog (Hh) signaling pathway. In the canonical pathway, binding of Hedgehog ligands (SHH, IHH, DHH) to the receptor Patched1 (PTCH1) relieves PTCH1-mediated inhibition of SMO, allowing SMO to activate downstream GLI transcription factors. SMO is a master regulator of neural development, adult neurogenesis, and neuroprotection, and its dysregulation has been implicated in neurodegenerative diseases, cerebellar pathology, and brain tumors.

Gene Structure and Expression

SMO spans approximately 25 kb on chromosome 7q32.1 and contains 12 exons encoding a 793 amino acid seven-transmembrane protein. The promoter region contains binding sites for Sp1, NF-Y, and AP-2 transcription factors. Alternative splicing generates minor transcript variants, though the canonical full-length isoform predominates in neural tissue.

In the developing brain, SMO is ubiquitously expressed in neural progenitor cells of the ventricular zone, the external granular layer of the cerebellum, and the subventricular zone (SVZ). In the adult brain, expression is maintained in neurogenic niches — the SVZ and the subgranular zone (SGZ) of the hippocampal dentate gyrus — as well as in astrocytes, Bergmann glia, and cerebellar Purkinje cells. The Allen Brain Atlas shows moderate expression across cortical regions with enrichment in the cerebellum, hippocampus, and hypothalamus.

Protein Function and Mechanism

Smoothened is a seven-transmembrane receptor belonging to the Frizzled class (class F) of GPCRs. The protein contains an extracellular cysteine-rich domain (CRD) that binds cholesterol and oxysterols, a seven-transmembrane core domain with a deep binding pocket for small-molecule modulators, and a long intracellular C-terminal tail that recruits downstream effectors.

Canonical Hedgehog Signal Transduction

In the absence of Hedgehog ligand, PTCH1 localizes to the primary cilium and suppresses SMO by depleting accessible cholesterol from the ciliary membrane. SMO remains in intracellular vesicles, and the GLI transcription factors are processed into repressor forms (GLI3R) by the SUFU–KIF7 complex and protein kinase A (PKA). When SHH binds PTCH1, PTCH1 exits the cilium, cholesterol accumulates, and SMO undergoes a conformational change enabling its translocation to the ciliary tip. Active ciliary SMO recruits and activates full-length GLI2/3 activators (GLI2A/GLI3A), which translocate to the nucleus and drive transcription of Hh target genes including GLI1, PTCH1, CCND1, and BCL2.

Non-Canonical SMO Signaling

Beyond the canonical GLI-dependent pathway, SMO activates several non-canonical effectors relevant to neurodegeneration:

• Gαi coupling: SMO activates heterotrimeric Gi proteins, reducing cAMP and modulating PKA activity independently of GLI

• Ca²⁺ signaling: SMO-Gαi coupling triggers phospholipase C (PLC) activation and inositol trisphosphate (IP3)-dependent Ca²⁺ release from the ER

• Small GTPases: SMO activates RhoA and Rac1 to regulate cytoskeletal dynamics, growth cone guidance, and axonal pathfinding

• AMPK activation: SMO can activate AMPK through a CaMKKβ-dependent mechanism, linking Hedgehog signaling to cellular energy sensing and autophagy

Ciliary Trafficking and Regulation

SMO activity is tightly regulated by its subcellular localization. Phosphorylation of the SMO C-terminal tail by CK1 and GRK2 promotes ciliary accumulation and full activation. Ubiquitination by the HECT-domain E3 ligases HERC4 and SMURF1/2 targets SMO for lysosomal degradation. Cholesterol and oxysterols (particularly 20(S)-hydroxycholesterol) serve as endogenous SMO agonists by binding the CRD, while the plant alkaloid cyclopamine and clinically approved drugs vismodegib and sonidegib are SMO antagonists that bind the transmembrane domain.

Role in Neural Development

SMO-mediated Hedgehog signaling is indispensable for multiple aspects of CNS development:

• Ventral patterning: SHH secreted from the notochord and floor plate activates SMO in neural progenitors, establishing the ventral identity of the neural tube. Graded SMO activation specifies distinct ventral neuronal subtypes including motor neurons and dopaminergic neurons of the ventral midbrain

• Cerebellar development: SMO activation in granule neuron precursors (GNPs) drives their massive postnatal expansion in the external granular layer. Constitutive SMO activation causes medulloblastoma — the most common malignant pediatric brain tumor

• Oligodendrocyte specification: SMO signaling in the ventral spinal cord specifies oligodendrocyte precursor cells (OPCs), which subsequently migrate dorsally and myelinate axons

• Adult neurogenesis: SMO remains active in the adult SVZ and SGZ, where it maintains the neural stem cell pool and regulates the production of new neurons throughout life

Disease Associations

Alzheimer’s Disease (AD)

Hedgehog signaling through SMO is progressively impaired in AD. Amyloid-beta (Aβ) oligomers directly inhibit SMO ciliary trafficking in hippocampal neurons, reducing GLI1 target gene expression and compromising neuroprotective programs. Postmortem AD brains show decreased SHH, SMO, and GLI1 expression in the hippocampus and entorhinal cortex. Pharmacological activation of SMO with the agonist SAG (Smoothened AGonist) rescues Aβ-induced neurotoxicity in primary hippocampal cultures and improves spatial memory in APP/PS1 transgenic mice. SMO agonism upregulates BDNF, reduces tau hyperphosphorylation via GSK-3β inhibition, and promotes adult hippocampal neurogenesis — suggesting that restoring Hedgehog signaling may counteract multiple AD pathomechanisms simultaneously.

Parkinson’s Disease (PD)

SMO-dependent Hedgehog signaling is critical for the development and maintenance of midbrain dopaminergic (DA) neurons. SHH is a survival factor for DA neurons, and conditional SMO deletion in the adult midbrain leads to progressive DA neuron loss reminiscent of PD. In PD models, α-synuclein aggregation impairs primary cilium structure, disrupting SMO ciliary trafficking and downstream GLI activation. The SMO agonist purmorphamine protects DA neurons against 6-OHDA and MPTP toxicity in both in vitro and in vivo models. Additionally, SMO signaling promotes the conversion of reactive astrocytes into functional DA neurons via Nurr1/Pitx3 upregulation — a finding with implications for cell replacement strategies in PD.

Amyotrophic Lateral Sclerosis (ALS)

Hedgehog signaling is dysregulated in the spinal cord of ALS patients and SOD1-G93A mice. SMO expression is reduced in motor neurons and surrounding astrocytes in the ventral horn. SHH supplementation or SMO agonist treatment (SAG) extends survival in SOD1 mice, associated with preserved motor neuron morphology, reduced GFAP-positive astrogliosis, and decreased NF-κB-driven neuroinflammation. SMO signaling in astrocytes promotes their conversion from the neurotoxic A1 to the neuroprotective A2 phenotype, reducing release of pro-inflammatory cytokines (TNF-α, IL-1β, C3).

Medulloblastoma and Brain Tumors

Gain-of-function mutations in SMO (e.g., W535L, the “SmoM2” mutation) cause constitutive ligand-independent activation and are found in approximately 10% of SHH-subgroup medulloblastomas. These mutations render SMO insensitive to PTCH1 inhibition and drive uncontrolled proliferation of cerebellar GNPs. FDA-approved SMO antagonists vismodegib and sonidegib are used clinically for basal cell carcinoma and are in trials for SHH-medulloblastoma.

Common Variants

Therapeutic Implications

SMO Agonists for Neurodegeneration

• SAG (Smoothened AGonist): Cell-permeable SMO agonist that rescues Aβ toxicity, protects DA neurons, and promotes adult neurogenesis in preclinical models. Brain-penetrant but limited by oncogenic risk

• Purmorphamine: Synthetic SMO agonist with DA neuroprotective effects in 6-OHDA models

• Oxysterols (20(S)-OHC): Endogenous SMO activators; supplementation restores Hedgehog signaling in aged mice

• Challenge: Balancing neuroprotective SMO activation against the oncogenic risk of sustained Hedgehog pathway activation, particularly in the cerebellum

SMO Antagonists for Cancer

• Vismodegib (Erivedge): FDA-approved SMO antagonist for advanced basal cell carcinoma; binds the transmembrane domain

• Sonidegib (Odomzo): Second-generation SMO antagonist with improved pharmacokinetics

• Drug resistance via SMO mutations (D473H, E518K) remains a clinical challenge

Combination Strategies

Pairing SMO agonists with downstream pathway modulators (GSK-3β inhibitors, HDAC inhibitors) may enable neuroprotection at lower SMO activation levels, reducing oncogenic risk while maintaining therapeutic benefit.

Expression Profile

See Also

• SHH — Sonic Hedgehog ligand, the primary activator of SMO

• PTCH1 — Patched1 receptor, direct inhibitor of SMO

• GLI1 — GLI transcription factor, primary Hedgehog target gene

• SUFU — Suppressor of Fused, negative regulator downstream of SMO

• GSK3B — GSK-3β kinase, integrates Wnt and Hedgehog signaling

• BDNF — Brain-derived neurotrophic factor, SMO target

• Hedgehog Signaling Pathway

External Links

• NCBI Gene: SMO

• UniProt: Q99835

• GeneCards: SMO

• OMIM: 601500

• Allen Brain Atlas: SMO